title: [Three cases of recurrent bile duct cancer diagnosed and treated by double-balloon endoscopy].
abstract: Local recurrences often develop after the resection of bile duct cancer. Imaging modalities do not have sufficient sensitivity or specificity to enable the definite diagnosis of recurrent bile duct cancer, and it may be difficult to decide when to start chemotherapeutic treatment. It is difficult to obtain specimens by conventional endoscopy after Roux-Y biliary reconstruction. The double-balloon endoscope(DBE) has 2 balloons: one at the tip of the endoscope and the other at the over- tube. The 2 balloons are inflated alternately and the endoscope can move through the small intestine in a caterpillar-like manner. DBE simplifies the approach to Roux-Y choledochojejunostomy and to obtaining a pathological specimen. Moreover, endoscopic biliary drainage and cholangiography can be performed with the DBE. Recently, the DBE has enabled systemic chemotherapy to be started after obtaining pathological evidence of malignancy, as well as biliary drainage instead of percutaneous transhepatic biliary drainage in cases with recurrent bile duct cancers. Here, we present 3 cases of recurrent bile duct cancer diagnosed and treated by a DBE.
authors.affiliation: Dept. of Surgery, Kobe University Graduate School of Medicine, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Shinozaki
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ajiki
authors.forename: Taro
authors.initials: T
authors.lastname: Okazaki
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Sae
authors.initials: S
authors.lastname: Murakami
authors.forename: Izuru
authors.initials: I
authors.lastname: Ohtsubo
authors.forename: Sachiyo
authors.initials: S
authors.lastname: Shirakawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Sawa
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Goto
authors.forename: Sadaki
authors.initials: S
authors.lastname: Asari
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Ueno
authors.forename: Hirochika
authors.initials: H
authors.lastname: Toyama
authors.forename: Makoto
authors.initials: M
authors.lastname: Shinzeki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kido
authors.forename: Ippei
authors.initials: I
authors.lastname: Matsumoto
authors.forename: Takumi
authors.initials: T
authors.lastname: Fukumoto
authors.forename: Takanobu
authors.initials: T
authors.lastname: Hayakumo
authors.forename: Yonson
authors.initials: Y
authors.lastname: Ku
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000628:therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine